$WGS
GeneDx Holdings Corp. Stock $wgs

$wgs Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000181833124000059 Filed on October 29, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$76.87M
YoY Change		44.22%
Cost Of Revenue		$29.05M
YoY Change		3.57%
Gross Profit		$47.83M
YoY Change		89.35%
Gross Profit Margin		62.22%
Selling, General & Admin		$43.17M
YoY Change		0.72%
% of Gross Profit		90.26%
Research & Development		$11.67M
YoY Change		-18.36%
% of Gross Profit		24.39%
Depreciation & Amortization		$2.422M
YoY Change		-53.12%
% of Gross Profit		5.06%
Operating Expenses		$54.84M
YoY Change		-4.05%
Operating Profit		-$7.780M
YoY Change		-81.89%
Interest Expense		-$843.0K
YoY Change		-151.4%
% of Operating Profit
Other Income/Expense, Net		-$579.0K
YoY Change		-213.75%
Pretax Income		-$8.359M
YoY Change		-80.31%
Income Tax		-$47.00K
% Of Pretax Income
Net Earnings		-$8.312M
YoY Change		-80.34%
Net Earnings / Revenue		-10.81%
Basic Earnings Per Share		-$0.31
Diluted Earnings Per Share		-$0.31
COMMON SHARES
Basic Shares Outstanding	27.47M shares	26.94M shares
Diluted Shares Outstanding		27.10M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$116.5M
YoY Change		1.89%
Cash & Equivalents		$57.89M
Short-Term Investments		$58.57M
Other Short-Term Assets		$12.62M
YoY Change		151.23%
Inventory		$10.77M
Prepaid Expenses		$7.678M
Receivables		$38.22M
Other Receivables		$260.0K
Total Short-Term Assets		$186.0M
YoY Change		8.26%
LONG-TERM ASSETS
Property, Plant & Equipment		$56.39M
YoY Change		57.75%
Goodwill
YoY Change
Intangibles		$162.1M
YoY Change		-7.96%
Long-Term Investments
YoY Change
Other Assets		$4.336M
YoY Change		-28.44%
Total Long-Term Assets		$222.8M
YoY Change		-9.22%
TOTAL ASSETS
Total Short-Term Assets		$186.0M
Total Long-Term Assets		$222.8M
Total Assets		$408.8M
YoY Change		-2.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$9.022M
YoY Change		-41.31%
Accrued Expenses		$11.08M
YoY Change		-16.87%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due		$1.205M
YoY Change		508.59%
Total Short-Term Liabilities		$77.34M
YoY Change		13.13%
LONG-TERM LIABILITIES
Long-Term Debt		$52.03M
YoY Change		759.78%
Other Long-Term Liabilities		$13.54M
YoY Change		-40.25%
Total Long-Term Liabilities		$65.57M
YoY Change		128.39%
TOTAL LIABILITIES
Total Short-Term Liabilities		$77.34M
Total Long-Term Liabilities		$65.57M
Total Liabilities		$204.3M
YoY Change		25.34%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.358B
YoY Change		6.55%
Common Stock		$2.000K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$204.5M
YoY Change
Total Liabilities & Shareholders Equity		$408.8M
YoY Change		-2.02%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$8.312M
YoY Change		-80.34%
Depreciation, Depletion And Amortization		$2.422M
YoY Change		-53.12%
Cash From Operating Activities		-$4.395M
YoY Change		-89.34%
INVESTING ACTIVITIES
Capital Expenditures		$646.0K
YoY Change		438.33%
Acquisitions
YoY Change
Other Investing Activities		-$7.109M
YoY Change		-73.69%
Cash From Investing Activities		-$7.755M
YoY Change		-71.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		13.97M
YoY Change		-1634.95%
NET CHANGE
Cash From Operating Activities		-4.395M
Cash From Investing Activities		-7.755M
Cash From Financing Activities		13.97M
Net Change In Cash		1.818M
YoY Change		-102.62%
FREE CASH FLOW
Cash From Operating Activities		-$4.395M
Capital Expenditures		$646.0K
Free Cash Flow		-$5.041M
YoY Change		-87.81%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	us-gaap	Inventory Net InventoryNet	10770000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	8777000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	24936000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26900000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	31452000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	32479000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	162106000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	172625000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39482
	dei	Entity Registrant Name EntityRegistrantName	GeneDx Holdings Corp.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1966622
	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 Ludlow Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	North Tower
	dei	Entity Address Address Line3 EntityAddressAddressLine3	6th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Stamford
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	30467000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20300000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10598000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	186010000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	182339000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4336000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4413000	usd
CY2024Q3	us-gaap	Assets Assets	408840000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	56416000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	37456000	usd
CY2024Q3	wgs	Lease Liabilities Current LeaseLiabilitiesCurrent	3698000	usd
CY2023Q4	wgs	Lease Liabilities Current LeaseLiabilitiesCurrent	3647000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	77342000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	58818000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52034000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13540000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14735000	usd
CY2024Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1054000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1560000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	190739000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27433803	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27433803	shares
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1357912000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1300188000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76874000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53303000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	29045000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	47829000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11665000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14288000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42967000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-579000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1134000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	509000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42458000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8359000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-47000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-8312000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57724000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-172000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	194043000	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001818331
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27471397	shares
CY2023Q4	us-gaap	Assets Assets	418756000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	204339000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	918000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	209810000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	145148000	usd
	us-gaap	Gross Profit GrossProfit	59252000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34134000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	49695000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32019000	usd
CY2024Q3	wgs	Change In Fair Value Of Warrants And Earn Out Contingent Liabilities ChangeInFairValueOfWarrantsAndEarnOutContingentLiabilities	-880000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-154953000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26024000	usd
CY2023Q3	wgs	Change In Fair Value Of Warrants And Earn Out Contingent Liabilities ChangeInFairValueOfWarrantsAndEarnOutContingentLiabilities	590000	usd
	wgs	Change In Fair Value Of Warrants And Earn Out Contingent Liabilities ChangeInFairValueOfWarrantsAndEarnOutContingentLiabilities	-11390000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4444000	usd
	wgs	Change In Fair Value Of Warrants And Earn Out Contingent Liabilities ChangeInFairValueOfWarrantsAndEarnOutContingentLiabilities	684000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58043000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-149994000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-150509000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-319000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-515000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-42286000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	459000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7853000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	493000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42286000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57231000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-149994000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-8312000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	86000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57724000	usd
	wgs	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	12586000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-500000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23777327	shares
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06902
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	729-1206
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57894000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99681000	usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	58566000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52688000	usd
CY2024Q3	wgs	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	60369000	usd
CY2023Q4	wgs	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	62938000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16763000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	45397000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	73760000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1668000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10402000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3636000	usd
CY2024Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-774000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	459000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7780000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12300000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14589000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14589000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	204501000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-42286000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	296113000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	431000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	254258000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	253705000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-149994000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	266000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	586000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7564000	usd
	wgs	Stock Issued During Period Value Stock Splits StockIssuedDuringPeriodValueStockSplits	6692000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25978863	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	425000	usd
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25978863	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1561493000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1527778000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	204501000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	228017000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	408840000	usd
	us-gaap	Gross Profit GrossProfit	128192000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46018000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	418756000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	28044000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	81618000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	85896000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	25259000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17025000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26145000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26099000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-5259000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	107129000	usd
CY2024Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	8282000	usd
CY2023Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2794000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2622000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1053000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2334000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1144000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	459000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14589000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	228017000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	493000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	296113000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-42286000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	431000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	254258000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	253705000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-149994000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	266000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	586000	usd
CY2024Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-843000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2092000	usd
	wgs	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	2750000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3636000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14589000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	204501000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	247000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6293000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14589000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-42286000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	254258000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	253705000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-149994000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	266000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	586000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7564000	usd
	wgs	Stock Issued During Period Value Stock Splits StockIssuedDuringPeriodValueStockSplits	6692000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	254258000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57724000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-149994000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	16395000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	27640000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6293000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	586000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11390000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-684000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-515000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	137000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	3634000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-12123000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
	wgs	Change In Third Party Payor Reserves ChangeInThirdPartyPayorReserves	-737000	usd
	wgs	Change In Third Party Payor Reserves ChangeInThirdPartyPayorReserves	6848000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	wgs	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10402000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1071000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10726000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2131000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-682000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7807000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.64
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	254258000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57724000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-149994000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	16395000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	27640000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6293000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	586000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11390000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-684000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	137000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	3634000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-12123000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
	wgs	Change In Third Party Payor Reserves ChangeInThirdPartyPayorReserves	-737000	usd
	wgs	Change In Third Party Payor Reserves ChangeInThirdPartyPayorReserves	6848000	usd
	wgs	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	0	usd
	wgs	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	2750000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10402000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2639000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1071000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5850000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10726000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2131000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-682000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7807000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-39913000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	1196000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25313000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	12144000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2441000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2874000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3887000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52725000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	598000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	24955000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	16665000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	0	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	461000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29613000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38862000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14589000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	143002000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	247000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	266000	usd
	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	198000	usd
	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	2000000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1499000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2133000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13139000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	139135000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-41787000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50016000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57724000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-149994000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6293000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	586000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	11390000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-684000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-319000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-515000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	3634000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-12123000	usd
	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
	wgs	Change In Third Party Payor Reserves ChangeInThirdPartyPayorReserves	-737000	usd
	wgs	Change In Third Party Payor Reserves ChangeInThirdPartyPayorReserves	6848000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	2954000	usd
	wgs	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	0	usd
	wgs	Gain Loss On Debt Forgiveness GainLossOnDebtForgiveness	2750000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10402000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2639000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1071000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5850000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10726000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2131000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-682000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7807000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	1196000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	1372000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25313000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-150289000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	12144000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2441000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2874000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3887000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52725000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	43935000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	598000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	24955000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	16665000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	0	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	461000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29613000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14589000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	143002000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	247000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	266000	usd
	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	198000	usd
	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	2000000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1499000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-41787000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50016000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100668000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138303000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-39913000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	1196000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	1372000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25313000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-150289000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	12144000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2441000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3887000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	52725000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	43935000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	598000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	24955000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	16665000	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	0	usd
	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	461000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29613000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14589000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	143002000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	247000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	266000	usd
	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	198000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1499000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	139135000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-41787000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-50016000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100668000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58881000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88287000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6068000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1116000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	910000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1178000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Stock Issued1 StockIssued1	6692000	usd
	wgs	Stock Consideration Paid Pursuant To Exercise Of Perceptive Warrant StockConsiderationPaidPursuantToExerciseOfPerceptiveWarrant	12586000	usd
	wgs	Stock Consideration Paid Pursuant To Exercise Of Perceptive Warrant StockConsiderationPaidPursuantToExerciseOfPerceptiveWarrant	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2612000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1220000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	689000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeneDx Holdings Corp., through its subsidiary GeneDx, LLC, is a leading genomics company—one that sits at the intersection of diagnostics and data science, pairing decades of genomic expertise with an ability to interpret clinical data at scale. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company believes it is well-positioned to accelerate the use of genomics and leverage large-scale clinical data to enable precision medicine as the standard of care. With a focus in pediatric and rare diseases today, the Company believes it has a competitive advantage in these two areas and can deliver on its vision. GeneDx, LLC serves healthcare professionals who work with their patients, bills third-party payors across the United States and offers solutions across the biopharma drug development pipeline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herein or unless the context otherwise requires, references in these notes to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“GeneDx Holdings” refers to GeneDx Holdings Corp., a Delaware corporation (f/k/a Sema4 Holdings Corp.);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“Legacy GeneDx” refers to GeneDx, LLC, a Delaware limited liability company (formerly, GeneDx, Inc., a New Jersey corporation), which we acquired on April 29, 2022 (the “Acquisition”);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“Legacy Sema4” refers to Mount Sinai Genomics, Inc. d/b/a Sema4, a Delaware corporation, which consummated the business combination with CM Life Sciences, Inc. (“CMLS”) on July 22, 2021 (the “Business Combination”); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“we,” “us” and “our,” the “Company” and “GeneDx” refer, as the context requires, to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy Sema4 prior to the Business Combination, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Business Combination; and</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy GeneDx prior to the Acquisition, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Acquisition.</span></div>
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100668000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138303000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58881000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88287000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6068000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1116000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	910000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1178000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Stock Issued1 StockIssued1	6692000	usd
	wgs	Stock Consideration Paid Pursuant To Exercise Of Perceptive Warrant StockConsiderationPaidPursuantToExerciseOfPerceptiveWarrant	12586000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2612000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1220000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	689000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeneDx Holdings Corp., through its subsidiary GeneDx, LLC, is a leading genomics company—one that sits at the intersection of diagnostics and data science, pairing decades of genomic expertise with an ability to interpret clinical data at scale. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company believes it is well-positioned to accelerate the use of genomics and leverage large-scale clinical data to enable precision medicine as the standard of care. With a focus in pediatric and rare diseases today, the Company believes it has a competitive advantage in these two areas and can deliver on its vision. GeneDx, LLC serves healthcare professionals who work with their patients, bills third-party payors across the United States and offers solutions across the biopharma drug development pipeline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herein or unless the context otherwise requires, references in these notes to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“GeneDx Holdings” refers to GeneDx Holdings Corp., a Delaware corporation (f/k/a Sema4 Holdings Corp.);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“Legacy GeneDx” refers to GeneDx, LLC, a Delaware limited liability company (formerly, GeneDx, Inc., a New Jersey corporation), which we acquired on April 29, 2022 (the “Acquisition”);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“Legacy Sema4” refers to Mount Sinai Genomics, Inc. d/b/a Sema4, a Delaware corporation, which consummated the business combination with CM Life Sciences, Inc. (“CMLS”) on July 22, 2021 (the “Business Combination”); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“we,” “us” and “our,” the “Company” and “GeneDx” refer, as the context requires, to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy Sema4 prior to the Business Combination, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Business Combination; and</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy GeneDx prior to the Acquisition, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Acquisition.</span></div>
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.31
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58881000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88287000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6068000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1116000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	910000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1178000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	us-gaap	Stock Issued1 StockIssued1	6692000	usd
	wgs	Stock Consideration Paid Pursuant To Exercise Of Perceptive Warrant StockConsiderationPaidPursuantToExerciseOfPerceptiveWarrant	12586000	usd
	wgs	Stock Consideration Paid Pursuant To Exercise Of Perceptive Warrant StockConsiderationPaidPursuantToExerciseOfPerceptiveWarrant	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2612000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1220000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	689000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GeneDx Holdings Corp., through its subsidiary GeneDx, LLC, is a leading genomics company—one that sits at the intersection of diagnostics and data science, pairing decades of genomic expertise with an ability to interpret clinical data at scale. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company believes it is well-positioned to accelerate the use of genomics and leverage large-scale clinical data to enable precision medicine as the standard of care. With a focus in pediatric and rare diseases today, the Company believes it has a competitive advantage in these two areas and can deliver on its vision. GeneDx, LLC serves healthcare professionals who work with their patients, bills third-party payors across the United States and offers solutions across the biopharma drug development pipeline.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herein or unless the context otherwise requires, references in these notes to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“GeneDx Holdings” refers to GeneDx Holdings Corp., a Delaware corporation (f/k/a Sema4 Holdings Corp.);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“Legacy GeneDx” refers to GeneDx, LLC, a Delaware limited liability company (formerly, GeneDx, Inc., a New Jersey corporation), which we acquired on April 29, 2022 (the “Acquisition”);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“Legacy Sema4” refers to Mount Sinai Genomics, Inc. d/b/a Sema4, a Delaware corporation, which consummated the business combination with CM Life Sciences, Inc. (“CMLS”) on July 22, 2021 (the “Business Combination”); and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">“we,” “us” and “our,” the “Company” and “GeneDx” refer, as the context requires, to:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy Sema4 prior to the Business Combination, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Business Combination; and</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">◦</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Legacy GeneDx prior to the Acquisition, and GeneDx Holdings and its consolidated subsidiaries following the consummation of the Acquisition.</span></div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3166381	shares
CY2023Q3	us-gaap	Restructuring Costs RestructuringCosts	2200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the valuation of stock-based awards, the valuation of warrant liabilities, income taxes and intangible assets. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates, judgments and assumptions.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating concentration of credit risk. Significant patients and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of September 30, 2024 and December 31, 2023 were primarily from large managed care insurance companies, institutional billed accounts, and data arrangements. The Company does not require collateral as a means to mitigate customer credit risk.</span></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the valuation of stock-based awards, the valuation of warrant liabilities, income taxes and intangible assets. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates, judgments and assumptions.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating concentration of credit risk. Significant patients and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of September 30, 2024 and December 31, 2023 were primarily from large managed care insurance companies, institutional billed accounts, and data arrangements. The Company does not require collateral as a means to mitigate customer credit risk.</span></div>
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76874000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53303000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	6300000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3000000.0	usd
CY2024Q3	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	300000	usd
CY2023Q3	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	400000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1000000.0	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1500000	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	666516	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	666515	shares
CY2024Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q3	wgs	Class Of Warrant Or Right Target Share Price Of Warrants Or Rights For Redemption ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption	594.00
	wgs	Redemption Price Per Warrant RedemptionPricePerWarrant	0.33
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, potential or actual claims for recoupment from third-party payors, the valuation of stock-based awards, the valuation of warrant liabilities, income taxes and intangible assets. Changes in estimates are recorded in the period in which they become known. Actual results could differ materially from those estimates, judgments and assumptions.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating concentration of credit risk. Significant patients and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of September 30, 2024 and December 31, 2023 were primarily from large managed care insurance companies, institutional billed accounts, and data arrangements. The Company does not require collateral as a means to mitigate customer credit risk.</span></div>
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76874000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53303000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	209810000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	145148000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3000000.0	usd
CY2024Q3	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	300000	usd
CY2023Q3	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	400000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1000000.0	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1500000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	666515	shares
CY2024Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q3	wgs	Class Of Warrant Or Right Target Share Price Of Warrants Or Rights For Redemption ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption	594.00
	wgs	Redemption Price Per Warrant RedemptionPricePerWarrant	0.33
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76874000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	145148000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	6300000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3000000.0	usd
CY2024Q3	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	300000	usd
CY2023Q3	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	400000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1000000.0	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1500000	usd
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	666516	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	666515	shares
CY2024Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2024Q3	wgs	Class Of Warrant Or Right Target Share Price Of Warrants Or Rights For Redemption ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption	594.00
	wgs	Redemption Price Per Warrant RedemptionPricePerWarrant	0.33
	wgs	Number Of Days For Written Notice Of Redemption NumberOfDaysForWrittenNoticeOfRedemption	30	day
	wgs	Common Stock Threshold Trading Days CommonStockThresholdTradingDays	30	day
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	82026000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	78931000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	50574000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	46452000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	31452000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	32479000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5900000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17100000	usd
CY2024Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	600000	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	600000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000000.0	usd
CY2023Q3	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	8300000	usd
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	9900000	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2422000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5166000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5876000	usd
	wgs	Number Of Days For Written Notice Of Redemption NumberOfDaysForWrittenNoticeOfRedemption	30	day
	wgs	Common Stock Threshold Trading Days CommonStockThresholdTradingDays	30	day
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	82026000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	78931000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	31452000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	32479000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5900000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17100000	usd
CY2024Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	600000	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	600000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000000.0	usd
CY2023Q3	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	8300000	usd
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	9900000	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2422000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5166000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5876000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17122000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	196000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	33894000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	162106000	usd
CY2017Q2	wgs	Related Party Transaction Funding Commitment To Be Received Maximum RelatedPartyTransactionFundingCommitmentToBeReceivedMaximum	55000000	usd
	wgs	Common Stock Threshold Trading Days CommonStockThresholdTradingDays	30	day
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	82026000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	78931000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	50574000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	46452000	usd
CY2024Q3	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	31452000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	32479000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5200000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5900000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17100000	usd
CY2024Q3	us-gaap	Depreciation Nonproduction DepreciationNonproduction	600000	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	600000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000000.0	usd
CY2023Q3	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	8300000	usd
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	9900000	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2422000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5166000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5876000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	196000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	33894000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	162106000	usd
CY2017Q2	wgs	Related Party Transaction Funding Commitment To Be Received Maximum RelatedPartyTransactionFundingCommitmentToBeReceivedMaximum	55000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	299000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1211000	usd
CY2024Q3	us-gaap	Restructuring Costs RestructuringCosts	400000	usd
CY2023Q3	us-gaap	Restructuring Costs RestructuringCosts	2200000	usd
	us-gaap	Restructuring Costs RestructuringCosts	1500000	usd
	us-gaap	Restructuring Costs RestructuringCosts	4500000	usd
CY2023Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	50	position
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	35	position
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.10
CY2023Q4	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-40000000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57894000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99681000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	987000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	196000000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	33894000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	162106000	usd
CY2017Q2	wgs	Related Party Transaction Funding Commitment To Be Received Maximum RelatedPartyTransactionFundingCommitmentToBeReceivedMaximum	55000000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	299000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1211000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1235000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1260000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	51285000	usd
CY2024Q3	wgs	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	762000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	56052000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	1205000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	2813000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52034000	usd
	us-gaap	Restructuring Costs RestructuringCosts	4500000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	299000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1211000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1235000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1260000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	51285000	usd
CY2024Q3	wgs	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	762000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	56052000	usd
CY2024Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	1205000	usd
CY2024Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	2813000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	52034000	usd
CY2024Q2	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	21000000	usd
CY2024Q3	wgs	Loss Contingency Damages Awarded To Be Paid By Insurance Value LossContingencyDamagesAwardedToBePaidByInsuranceValue	10000000	usd
	wgs	Litigation Settlement Insurance Proceeds From Other Party LitigationSettlementInsuranceProceedsFromOtherParty	1400000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6293000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	586000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1235000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1260000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	51285000	usd
CY2024Q2	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	21000000	usd
CY2024Q3	wgs	Loss Contingency Damages Awarded To Be Paid By Insurance Value LossContingencyDamagesAwardedToBePaidByInsuranceValue	10000000	usd
	wgs	Litigation Settlement Insurance Proceeds From Other Party LitigationSettlementInsuranceProceedsFromOtherParty	1400000	usd
	us-gaap	Litigation Settlement Loss LitigationSettlementLoss	2600000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3636000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	431000	usd
CY2023Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	50	position
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	35	position
CY2024Q2	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	21000000	usd
	wgs	Litigation Settlement Insurance Proceeds From Other Party LitigationSettlementInsuranceProceedsFromOtherParty	1400000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3636000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-300000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0056
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-8312000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27095986	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27095986	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25788747	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25788747	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23777327	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0056
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-8312000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-42286000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27095986	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27095986	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25788747	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25788747	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26593877	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23777327	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.64
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.64
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3166381	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2987526	shares
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0056
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0035
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-8312000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-57724000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-149994000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27095986	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27095986	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25788747	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26593877	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23777327	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.64
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.31
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.31
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3166381	shares
CY2023Q3	us-gaap	Restructuring Costs RestructuringCosts	2200000	usd
	us-gaap	Restructuring Costs RestructuringCosts	4500000	usd
CY2023Q3	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	50	position
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	35	position
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.10
CY2023Q4	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-40000000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57894000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99681000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	987000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	987000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58881000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100668000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7678000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	12622000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1958000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20300000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10598000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9022000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10238000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11075000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12154000	usd
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.10
CY2023Q4	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-40000000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57894000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99681000	usd
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	987000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	987000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58881000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7678000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8640000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	12622000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1958000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20300000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10598000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9022000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10238000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11075000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12154000	usd
CY2024Q3	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	23573000	usd
CY2023Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	25000	usd
CY2024Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	12746000	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	15039000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	56416000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	37456000	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12821000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12465000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	987000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58881000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100668000	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7678000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8640000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	12622000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1958000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20300000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10598000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9022000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10238000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11075000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12154000	usd
CY2024Q3	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	23573000	usd
CY2023Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	25000	usd
CY2024Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	12746000	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	15039000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	56416000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	37456000	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12821000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12465000	usd
CY2024Q3	wgs	Accrued Severance Current AccruedSeveranceCurrent	615000	usd
CY2023Q4	wgs	Accrued Severance Current AccruedSeveranceCurrent	1853000	usd
CY2024Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3065000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	2018000	usd
CY2024Q3	wgs	Warrant Liability WarrantLiability	1540000	usd
CY2023Q4	wgs	Warrant Liability WarrantLiability	2735000	usd
CY2024Q3	wgs	Third Party Payor Reserve Non Current ThirdPartyPayorReserveNonCurrent	12000000	usd
CY2024Q3	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	23573000	usd
CY2023Q4	us-gaap	Settlement Liabilities Current SettlementLiabilitiesCurrent	25000	usd
CY2024Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	12746000	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	15039000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	56416000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	37456000	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12821000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	12465000	usd
CY2024Q3	wgs	Accrued Severance Current AccruedSeveranceCurrent	615000	usd
CY2023Q4	wgs	Accrued Severance Current AccruedSeveranceCurrent	1853000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	2018000	usd
CY2024Q3	wgs	Warrant Liability WarrantLiability	1540000	usd
CY2023Q4	wgs	Warrant Liability WarrantLiability	2735000	usd
CY2024Q3	wgs	Third Party Payor Reserve Non Current ThirdPartyPayorReserveNonCurrent	12000000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13540000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14735000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q3	us-gaap	Gross Profit GrossProfit	47829000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	25259000	usd
	us-gaap	Gross Profit GrossProfit	128192000	usd
	us-gaap	Gross Profit GrossProfit	59252000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	wgs	Accrued Severance Current AccruedSeveranceCurrent	615000	usd
CY2023Q4	wgs	Accrued Severance Current AccruedSeveranceCurrent	1853000	usd
CY2024Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3065000	usd
CY2023Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	2018000	usd
CY2024Q3	wgs	Warrant Liability WarrantLiability	1540000	usd
CY2023Q4	wgs	Warrant Liability WarrantLiability	2735000	usd
CY2024Q3	wgs	Third Party Payor Reserve Non Current ThirdPartyPayorReserveNonCurrent	12000000	usd
CY2023Q4	wgs	Third Party Payor Reserve Non Current ThirdPartyPayorReserveNonCurrent	12000000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13540000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14735000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q3	us-gaap	Gross Profit GrossProfit	47829000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	25259000	usd
	us-gaap	Gross Profit GrossProfit	128192000	usd
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	wgs	Third Party Payor Reserve Non Current ThirdPartyPayorReserveNonCurrent	12000000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	13540000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14735000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q3	us-gaap	Gross Profit GrossProfit	47829000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	25259000	usd
	us-gaap	Gross Profit GrossProfit	128192000	usd
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001818331-24-000059-index-headers.html	Edgar Link	pending
0001818331-24-000059-index.html	Edgar Link	pending
0001818331-24-000059.txt	Edgar Link	pending
0001818331-24-000059-xbrl.zip	Edgar Link	pending
exhibit311-ceocertificatio.htm	Edgar Link	pending
exhibit312-cfocertificatio.htm	Edgar Link	pending
exhibit321-ceocertificatio.htm	Edgar Link	pending
exhibit322-cfocertificatio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
wgs-20240930.htm	Edgar Link	pending
wgs-20240930.xsd	Edgar Link	pending
wgs-20240930_g1.jpg	Edgar Link	pending
wgs-20240930_cal.xml	Edgar Link	unprocessable
wgs-20240930_def.xml	Edgar Link	unprocessable
wgs-20240930_lab.xml	Edgar Link	unprocessable
wgs-20240930_pre.xml	Edgar Link	unprocessable
wgs-20240930_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WGS
GeneDx Holdings Corp. Stock $wgs

2024 Q4 Form 10-Q Financial Statement

#000181833124000059 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WGS GeneDx Holdings Corp. Stock $wgs

2024 Q4 Form 10-Q Financial Statement

#000181833124000059 Filed on October 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WGS
GeneDx Holdings Corp. Stock $wgs